전립선암 치료제 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Prostate Cancer Therapeutics Market size was valued at USD 14.63 Billion in 2024 and is poised to grow from USD 15.86 Billion in 2025 to USD 30.23 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The Global Prostate Cancer Therapeutics Market is experiencing significant transformation, driven by a growing aging population, heightened awareness of early detection, and breakthroughs in medical technology. This market offers diverse treatment options-including surgery, radiation, chemotherapy, hormone therapy, immunotherapy, and targeted therapy-catering to the various needs of patients and healthcare providers. The rise of precision medicine facilitates tailored treatments, enhancing patient outcomes. Key pharmaceutical firms, research entities, and academic partnerships are pivotal in this evolving landscape. However, challenges persist, including high costs, treatment side effects, and the urgent need for reliable biomarkers. Innovations such as advanced drug delivery systems, artificial intelligence in diagnostics, and combination therapies promise to reshape the therapeutic approaches for prostate cancer, highlighting the market's dynamic potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Therapeutics Market Segments Analysis

Global Prostate Cancer Therapeutics Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Therapeutics Market

A significant factor propelling the Prostate Cancer Therapeutics market is the rise in the aging population. With advancing age, the likelihood of developing prostate cancer elevates, resulting in a growing number of patients in need of treatment options. This demographic shift, especially pronounced in developed areas, enhances the demand for therapeutic solutions for prostate cancer. As more individuals enter older age brackets, the healthcare system is increasingly focusing on providing effective therapies, thereby driving market growth and innovation in treatment approaches. This trend underscores the urgent need for advancements in prostate cancer therapeutics to meet the evolving challenges linked to this condition.

Restraints in the Prostate Cancer Therapeutics Market

A significant constraint in the Prostate Cancer Therapeutics market is the substantial cost associated with various treatment options. The expenses incurred during diagnosis, surgical procedures, radiation treatments, chemotherapy, hormone therapies, and targeted therapies can be overwhelming, creating financial burdens for both patients and healthcare providers. This high cost can restrict access to necessary care, particularly in areas with limited medical resources or among patients lacking sufficient insurance coverage. Consequently, these economic barriers may impede overall market growth and negatively impact patient outcomes, making it challenging for individuals to receive the best possible therapeutic interventions in their fight against prostate cancer.

Market Trends of the Prostate Cancer Therapeutics Market

A notable trend in the Prostate Cancer Therapeutics Market is the growing emphasis on precision medicine, which seeks to customize treatment strategies based on individual patient traits, including genetic profiles and specific biomarkers. This shift towards personalized and targeted therapies aims to improve efficacy while reducing adverse effects, thereby enhancing overall treatment outcomes. Advances in molecular profiling technologies and a deeper understanding of the genetic mutations linked to prostate cancer are driving this movement, fostering the development of innovative therapies that cater to each patient's unique characteristics. The integration of these approaches is likely to reshape the therapeutic landscape and improve patient care significantly.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Prostate Cancer Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Hormonal Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Chemotherapy
  • Taxotere
  • Jevtana
• Immunotherapy
  • Provenge
• Targeted Therapy
  • Xofigo
• Others

Global Prostate Cancer Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD (Merck & Co., Inc.) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Healthcare (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations